By fostering an immunosuppressive environment, MDSCs inhibit the activity of anti-tumor immune cells, including CD8+ T cells, and contribute to resistance to therapeutic interventions, making them a significant target for cancer treatment strategies [4, 10, 84]. The gene discussed is CD8A; the disease is neoplasm.